The present invention disclosed herein relates to synergistic compositions for cerebrovascular diseases. In particular, the invention relates to synergistic, efficient, composition for treating cerebral ischemia or stroke comprising specific combination of standardized celery seed extract (CSE) enriched with Dl N-Butylphthalide (NBP) and SIRT1 activators, wherein Dl-3-N-Butylphthalide (NBP) and SIRT1 activator are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

The present invention disclosed herein relates to synergistic compositions for cerebrovascular diseases. In particular, the invention relates to synergistic, efficient, composition for treating cerebral ischemia or stroke comprising specific combination of standardized celery seed extract (CSE) enriched with Dl N-Butylphthalide (NBP) and SIRT1 activators, wherein Dl-3-N-Butylphthalide (NBP) and SIRT1 activator are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

Compositions and methods for preventing or relieving hangover symptoms are provided. The composition comprises a flavonoid such as dihydromyricetin, an antioxidant comprising a substituted pyridine, such as emoxypine succinate, and a mononucleotide such as nicotinamide mononucleotide. The composition may be administered to a subject in need thereof as an oral formulation.

Compositions and methods for preventing or relieving hangover symptoms are provided. The composition comprises a flavonoid such as dihydromyricetin, an antioxidant comprising a substituted pyridine, such as emoxypine succinate, and a mononucleotide such as nicotinamide mononucleotide. The composition may be administered to a subject in need thereof as an oral formulation.

Compositions and methods for preventing or relieving hangover symptoms are provided. The composition comprises a flavonoid such as dihydromyricetin, an antioxidant comprising a substituted pyridine, such as emoxypine succinate, and a mononucleotide such as nicotinamide mononucleotide. The composition may be administered to a subject in need thereof as an oral formulation.

Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes in patients having such diseases or disorders, as such up-regulation leads to a process called pyroptosis: death and malfunction of immune system cells, particularly of certain types of lymphocytes. An inhibitor of caspase such as a caspase 1 inhibitor, or “pan-caspase” inhibitor (i.e., an inhibitor of multiple caspase types including caspase-1), can be used to treat COVID-19 patients or individuals at risk of infection, by limiting the malfunction of the immune system. A caspase-1 or pan-caspase inhibitor is advantageously administered before or very early in the course of infection by a positive-sense, single-stranded RNA virus such as SARS-CoV, MERS-CoV, or SARS-Cov-2.

Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes in patients having such diseases or disorders, as such up-regulation leads to a process called pyroptosis: death and malfunction of immune system cells, particularly of certain types of lymphocytes. An inhibitor of caspase such as a caspase 1 inhibitor, or “pan-caspase” inhibitor (i.e., an inhibitor of multiple caspase types including caspase-1), can be used to treat COVID-19 patients or individuals at risk of infection, by limiting the malfunction of the immune system. A caspase-1 or pan-caspase inhibitor is advantageously administered before or very early in the course of infection by a positive-sense, single-stranded RNA virus such as SARS-CoV, MERS-CoV, or SARS-Cov-2.

The present invention relates to pharmaceutical compositions with isolated and treated whole blood cells or Peripheral Blood Mononuclear Cells (PBMCs) as well as such pharmaceutical compositions for use in the prevention and/or treatment of organ or cell graft rejection in a human graft recipient.

The present invention relates to pharmaceutical compositions with isolated and treated whole blood cells or Peripheral Blood Mononuclear Cells (PBMCs) as well as such pharmaceutical compositions for use in the prevention and/or treatment of organ or cell graft rejection in a human graft recipient.

The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.